Research sponsors

Silver sponsors

Host sponsor

Video sponsor

Accredited by

Overview

**Please note this event has now passed.**

Now in its fourth year, War On Cancer Europe 2018, is part of our global series to catalyse fresh debate around strengthening cancer control. The event will bring together clinicians, patients, service providers, industry representatives, employers and policymakers.

About War on Cancer 2018:

Despite significant strides in prevention and in survivorship, cancer remains a leading cause of death across Europe. With nearly 200 variations of cancer, the complexity of navigating treatments and optimising resources has risen to the forefront of public debate. Technological innovations--from AI, to wearables, to advancements in immunotherapy, to CAR-T and radiotherapy treatments, are rapidly redefining patient experiences.

As the digital revolution accelerates, the opportunities for patients to take ownership of their diagnosis, treatments and oncology journey have grown. How will current data privacy laws such as GDPR impact patient treatments? How can stakeholders work collaboratively to ensure patient engagement is more than a moral imperative but a tool for driving progress in oncology care? Will increased patient access to data strengthen relationships with clinicians or create new tensions for care? What can be learned from regions in Europe like the Nordics, that are taking the lead on meaningful patient collaboration and engagement with emerging technologies? How can patient engagement strengthen drug discovery, R&D and regulation?

This event is certified by the CPD and eligible for 5.5 CPD points.

(Download the kit to get access to: event brochure, special report on targeting tumour from The Economist, 3 articles on healthcare from The Economist, 2018 confirmed attendees list, 2017 event summary, special discount code)

Speakers

Chris Fearne

Deputy prime minister and minister of health, Malta

Chris Fearne

Deputy prime minister and minister of health, Malta

Minister Christopher Fearne was born in Attard, Malta on 12 March 1963. In April 2016 he was appointed minister for health after holding the position of parliamentary secretary for health since April 2014. In June 2017 he was re-appointed minister for health following the general elections and in July 2017 he was elected deputy prime minister following the Malta Labour Party’s extraordinary general council. Prior to this, Hon. Fearne worked as a consultant paediatric surgeon and clinical chairman at Mater Dei Hospital. He is a member of parliament for the ruling Labour Party and was the chairman of the foreign and European affairs committee at the Maltese house of representatives. Hon. Fearne has worked as a doctor and surgeon for over 30 years. He received his formal education at St. Aloysius College and at the University of Malta graduating in medicine and surgery in 1987, becoming a fellow of The Royal College of Surgeons of Edinburgh. He worked and studied in a number of children’s hospitals in England, including the Great Ormond Street Hospital in London. He also lectures students of medicine at the University of Malta.

Liselott Blixt

Chair, health and senior citizen's committee, and member of parliament, Denmark

Liselott Blixt

Chair, health and senior citizen's committee, and member of parliament, Denmark

Liz Barrett

Chief executive officer, Novartis Oncology

Liz Barrett

Chief executive officer, Novartis Oncology

Liz Barrett has been chief executive officer of Novartis Oncology since February 1, 2018. She is a member of the executive committee of Novartis.

Ms. Barrett previously served as global president of oncology at Pfizer Inc. At Pfizer, she held other leadership positions, including president of global innovative pharma for Europe, president of the specialty care business unit for North America, and president of United States oncology. Prior to Pfizer, she was vice president and general manager of the oncology business unit at Cephalon Inc. from 2006 to 2009, and before that, she worked at Johnson & Johnson. She started her career at Kraft Foods Group Inc. in 1984.

Ms. Barrett holds a Bachelor of Science from the University of Louisiana and a Master of Business Administration from Saint Joseph’s University, both in the US

Jonathan Pearce

Regional Director Europe, Lymphoma Coalition Europe

Jonathan Pearce

Regional Director Europe, Lymphoma Coalition Europe

Jonathan has over 15 years’ experience as a charity chief executive in the UK. Before
starting work for Lymphoma Coalition Europe in March 2018, he was the chief executive of
Lymphoma Action (formerly the Lymphoma Association) for four years, and before that
Adoption UK and Cabrini Children’s Society. In his LCE role, he is a member of the
European Cancer Organisation’s (ECCO) Patient Advisory Committee and of the European
Haematology Association’s European Affairs Committee.
He is also Chair of Cancer52 (a UK national alliance of charities representing rare and less
common cancers), and has a background in the voluntary sector, law, publishing and
journalism.

Ricky Sharma

Chair of radiation oncology, University College London

Ricky Sharma

Chair of radiation oncology, University College London

Professor Ricky Sharma is Chair of Radiation Oncology at University College London and the Head of Academic Radiotherapy at the UCL Cancer Institute. He is an Honorary Consultant in Clinical Oncology at University College London Hospitals and the Royal Free Hospital, where he has a clinical practice in radiotherapy and chemotherapy. He graduated in medicine from the University of Cambridge, United Kingdom. He trained in general internal medicine, medical oncology and radiation oncology and completed a PhD on DNA damage repair. Prior to his current post, Professor Sharma was an Associate Professor and Scientific Group Leader at the University of Oxford, where he was an Honorary Consultant in Clinical Oncology. Professor Sharma is an international authority on the translation of radiobiology from the laboratory to the clinic and on the multi-modality treatment of cancer with precision therapy.

Giske Ursin

Director, Norwegian Cancer Registry

Giske Ursin

Director, Norwegian Cancer Registry

Giske Ursin is the director of the Cancer Registry of Norway, which is among the oldest cancer registries in the world and collects data on incidence and treatment of cancer, and administers the national cancer screening programmes. She is also a professor at the Institute of Basic Medical Sciences of the University of Oslo, and professor emeritus of the Department of Preventive Medicine at the University of Southern California. Ms Ursin is an internationally recognised cancer epidemiologist and is a member of the Norwegian Society of Science and Letters. Her research has focused on the epidemiology of cancer subgroups, defined by pathological or genetic characteristics, as well as early markers for cancer. In addition, she currently serves as vice-chair of the Scientific Council of the International Agency for Research on Cancer, and is also a member of the Danish Cancer Society Scientific Committee and the steering group of the National Cancer Institute Cohort Consortium.

Steven Hildemann

Deborah James

Host, You, Me and the Big C

Deborah James

Host, You, Me and the Big C

Deborah James was a deputy head teacher leading national research teams into growth mindsets in schools. Then, in 2016, at the age of 35, she was diagnosed with bowel cancer and her life with her young children and husband was thrown upside down. She's had 4 major operations including bowel and lung resections, multiple rounds of chemo and Cyberknife - and is still undergoing treatment at the Royal Marsden. Rather than disappear into a cancer cave she started a blog, 'bowel babe' to debunk the myth that young women don't get bowel cancer and writes a weekly column for the Sun online, Things Cancer Made Me Say. He first book “She campaigns alongside major UK cancer charities, writes and presents the award winning podcast 'You, Me & the Big C' for BBC's Radio 5 Live, and has a built up a strong following on Instagram @bowelbabe. Her best selling book - “F*** You Cancer” a self help guide to living your best life WITH cancer, published by Penguin is out now.

Lauren Mahon

Host, You, Me and the Big C

Lauren Mahon

Host, You, Me and the Big C

Lauren has never been a big fan of her boobs. If you can even call them that. They’re more of a nod to a boob, a flabby-nipple-type situation, a goodwill gesture. So on the 31st August 2016 when following a biopsy a Dr uttered the words “I’m sorry, it’s not good news, it’s cancer” she was sure they were having a f*cking laugh.

Surely this must be the universe’s idea of a cruel joke. Right? Firstly Lauren was thirty-bloody-one, far too young and full-of-fun to be dealing with this kind of crap, and secondly, how can she have breast cancer when she DOESN’T HAVE ANY B*STARD TITS?!?!

But Lauren did have breast cancer. An aggressive 2.8cm ‘Grade 3’ cancerous lump set up residence in her right chesticle, without consent, and sent her life as she knew it into a tailspin.

Desperate for some reassurance and carcinoma companionship Lauren went looking for like-minded women who had faced the c-bomb for advice and encouragement. Unfortunately she mostly found doomsaying online communities and clinical materials that were aimed at women in a more advanced lifestage. It didn’t speak to her. At all.

Fed up of the perception that cancer is a disease for the over fifties Lauren decided to grab her breast cancer diagnosis by the boobs and began sharing the nuances of her cancer beating crusade on her blog and instagram under the hashtag #GIRLvsCANCER. Lauren’s aim was to share the tales of her treatment in an authentic and accessible way in an attempt to tackle the cancer taboo and create a better understanding of the challenges facing those diagnosed with cancer in their 20’s + 30’s.

Lauren also wanted her miniature space on’t interweb to empower her peers. Encourage them to take responsibility for their bodies. Know them like they know all the lyrics to Drake’s Hotline Bling because by being in tune with yourself you’ll know when something is in need of examining.

After all if a fit and feisty Lauren could get cancer, anyone can.

And thus GIRLvsCANCER was born – a place for fierce women affected by the cretin that is cancer to feel empowered to deal with the sh*t show that a cancer diagnosis means.

Bryan Deane

Head of product & process innovation, Association of the British Pharmaceutical Industry

Bryan Deane

Head of product & process innovation, Association of the British Pharmaceutical Industry

After graduating in Pharmacology and completing a PhD in Neuropathology, Bryan embarked on a long and successful career in the pharmaceutical industry. A series of increasingly senior positions at SmithKline Beecham and GlaxoSmithKline were mostly focussed on medical marketing and commercial development, covering a variety of therapy areas including infectious diseases, oncology, respiratory and diabetes. These positions included experience in a wide range of countries and regions, from the UK and Europe to China and from Latin America to Asia-Pacific. Over the last 10 years, Bryan has led a variety of projects as a freelance consultant, including support for new product launches, medical affairs and restructuring healthcare agencies. Since 2012, a joint project with the ABPI investigating the topic of clinical trial transparency led to four peer-reviewed publications, and Bryan joined the ABPI’s Research, Medical & Innovation Team in May 2018, with a focus on Antimicrobial Resistance and Advanced Therapy Medicinal Products.

Sarunas Narbutas

Sarunas Narbutas

Šarūnas Narbutas is a professional lawyer, a political advisor and a cancer patient advocate, who has lived with chronic myelogenous leukemia (CML) for more than 10 years. Šarūnas is a President of Lithuanian Cancer Patient Coalition (POLA), deputy chairman of Lithuanian Patients’ Forum, co-founder of Youth Cancer Europe and holds several other management positions at international patient organisations, while serving on a dozen governmental committees or working groups. Until 2017, Šarūnas Narbutas has also served as a political advisor to the President of the Republic of Lithuania. Outside of the patient advocacy activities, Šarūnas is a chairman of Government Fund on the Promotion of Public Health, is a Member of National Health Council, a member of Lithuanian E-Health Management Board and a business ambassador for Governmental Agency “Invest Lithuania”. Šarūnas currently works on his PhD thesis on Networked Government and delivers lectures in Vilnius University Faculty of Law on Health Law, European Union Law and Public International Law.

Mark Haefele

Mark Haefele is the Chief Investment Officer of UBS Global Wealth Management and the Chair of the UBS Global Investment Committee. In this capacity, Mark oversees the investment strategy for USD 2.4 trillion in invested assets, including UBS's oncology impact investing strategy.

Mark joined UBS as Head of Investment for UBS Wealth Management's Chief Investment Office when it was founded in 2011. Before joining UBS, Mark was the co-founder and co-fund manager at Sonic Capital. He also served as a Managing Director at Matrix Capital Management and began his career as a lecturer and subsequently acting dean at Harvard University.

Mark received a BA from Princeton and both an MA and a PhD from Harvard. As a Fulbright Scholar, he also received an MA from the Australian National University.

Bengt Jönsson

Professor emeritus of health economics, Stockholm School of Economics

Bengt Jönsson

Professor emeritus of health economics, Stockholm School of Economics

Bengt Jönsson is professor emeritus of Health Economics at the Stockholm School of Economics (SSE). Before joining the SSE in 1990, he was a professor at Linköping University in the Department of Health and Society for eight years. He was previously director of the Swedish Institute for Health Economics (IHE) in Lund and a member of the IHE Board, where he is now chair of the scientific advisory board. Mr Jönsson is also a member of the European Academy of Cancer Sciences, and vice-chair of the EU Expert Panel on effective ways of investing in health. Mr Jönsson is a former president of the Swedish Health Economics Association and of the international Health Economists’ Association. Other previous positions include membership of the Karolinska University Hospital Board and the Scientific Advisory Board, and the National Board of Health and Welfare of Sweden, as well as the chair of the expert group to the Committee on Funding and Organisation of Health Services in Sweden. In addition, he was a member of the National Social Insurance Board, and the Scientific Advisory Board of the Swedish Council on Technology Assessment in Health Care. Mr Jönsson is a member of the editorial boards of several journals, including the Journal of Cancer Policy, the European Journal of Health Economics, and the International Journal of Technology Assessment in Health Care, and has been a temporary adviser to the WHO and a consultant to the OECD and UNIDO.

Maha El Rabbat

Executive director , MENA Health Policy Forum

Maha El Rabbat

Executive director , MENA Health Policy Forum

Professor Dr. Maha El Rabbat is a Professor of Public Health at the Faculty of Medicine, Cairo University. She is an Ex–Minister of Health and Population for the government of Egypt and is now the Executive Director of the MENA Health Policy Forum. She has held several high-level academic and leadership positions as the Head of the Public Health Department, Faculty of Medicine, and Cairo University and worked closely with national, regional, and international organizations as an expert in health system strengthening, governance, system wide assessments and reform. She currently serves as the Executive Director of the Middle East and North Africa Health Policy Forum (MENA HPF), a regional NGO with a regional mandate. Through her position and within the forum’s mandate she seeks to strengthen health systems for human development particularly in lower and middle income countries and those in fragile contexts to support regional efforts toward the progressive realization of right to health and universal healthcare through expansion of evidence-based policy platform, knowledge exchange, networking, research, and capacity building. El Rabbat is a member of several national and regional networks including OIC networks, EMRO research consortium and others.

Mark Lee

Senior vice president, head of personalized health care, Roche

Mark Lee

Senior vice president, head of personalized health care, Roche

Mark Lee is a medical oncologist and the Global Head for Personalized Healthcare, Product Development at Genentech/Roche. Prior to joining Genentech, Mark was a member of the founding leadership team and Head of Clinical Development and Medical Affairs at GRAIL, where he built one of the largest clinical research programs in genomic medicine aimed at early cancer detection. Mark’s previous roles include Lead for Oncology Clinical Sciences at Google[x] Life Sciences, Chief Medical Officer at Boreal Genomics, and Vice President of Oncology Development at Genomic Health, where he led the successful development and validation of the Oncotype DX Colon and Prostate Cancer Assays. His prior work also includes design and conduct of clinical trials for tissue-based and molecular imaging biomarker discovery at Genentech. Mark holds a PhD in Biological Chemistry and Molecular Pharmacology from Harvard, and a MD from Stanford University, where he completed his internal medicine training and medical oncology fellowship.

Mitesh Patel

Medical director, Aetna International

Mitesh Patel

Medical director, Aetna International

As medical director for Aetna International, Mitesh provides guidance, support, and medical leadership for care management activities in Europe. Mitesh also manages Aetna International’s emergency evacuation program, helping to ensure appropriate healthcare delivery for our members around the globe. Mitesh is an established “Thought Leader” having published numerous whitepapers which cover topical issues ranging from expatriate mental health, globesity and the ticking time bomb of the ageing population. Dr. Patel graduated from King’s College University, London and also has a Healthcare Management degree from Imperial College, London. He is also a practicing physician in Emergency Medicine.

Mark Gooding

Chief scientist, Mirada Medical

Mark Gooding

Chief scientist, Mirada Medical

Dr Gooding obtained his DPhil in Medical Imaging from University of Oxford in 2004. He was employed as a postdoctoral researcher both in university and NHS settings, where his focus was largely around women’s health. In 2009, he joined Mirada Medical, motivated by a desire to see technical innovation translated into clinical practice. While there, he has worked on a broad spectrum of clinical applications, developing algorithms and products for both diagnostic and therapeutic purposes. If given a free choice of research topic, his passion is for improving image segmentation, but in practice he is keen to address any technical challenge. Dr Gooding now leads the research team at Mirada, where in addition to the commercial work he continues to collaborate both clinically and academically.

Sukhveer Singh

Sukhveer Singh

Sukhveer Singh is the vice-president and general manager for the Oncology Continuum Solutions (OCS) business unit at Varian Medical Systems located in Palo Alto, California. The mission of OCS is to enable global providers of cancer treatment to deliver high-quality, cost-effective, patient centric, coordinated multi-disciplinary care. Sukhveer is a technology enthusiast and maven. He believes in the transformational potential of informatics and is an evangelist for the adoption of mobility, big data, cloud-computing, and personalized medicine within healthcare.

Sukhveer has more than 18 years of international leadership experience in the healthcare and strategic consulting space, most notably with companies such as Philips, Siemens, and Bridge Strategy. He has expertise in product marketing, product development, service marketing, complete life-cycle software development, offshoring management, and cross-functional team management. He also plays an active role in organization wide strategic and operational initiatives like change management, value based pricing, and business processes optimization. Sukhveer has a B.S. in Engineering from Netaji Subhas Institute of Technology, an M.S. in Computer Science from Illinois Institute of Technology, and is a 2004 MBA graduate from the Kellogg School of Management at Northwestern University.

Agenda

Registration and refreshments

9:00 AM

Chairman’s opening remarks

Vivek Muthu

Chair, The Economist Intelligence Unit Healthcare

Vivek Muthu

Chair, The Economist Intelligence Unit Healthcare

Vivek Muthu worked as a doctor in the UK National Health Service, including London’s Queen Square, the Hammersmith and Oxford University hospitals, before joining the British Medical Journal, where he helped to develop and lead a team examining the clinical value of drugs and devices. Dr Muthu then went on to found Bazian, a company dedicated to developing and servicing the needs of the emerging paradigm of value-based health internationally. Following its acquisition by The Economist Group, Bazian lies at the heart of the Economist Intelligence Unit’s value-based health-care business, for which Dr Muthu took overall leadership and strategic responsibility. After launching EIU Healthcare, he has now taken up a non-executive advisory role as chair of the business. He also sits on the steering panels for a number of UK-based initiatives in value-based health. In the past, he has additionally served as a health-care consultant to the European Bank for Reconstruction and Development.

9:10 AM

Setting the scene

Advances in medical technology and the promise of big data analysis places patients, researchers and clinicians at a turning point in cancer research, diagnosis and treatment. Innovations in AI and wearables are heralded as reinvigorating patient engagement, but the long-term potential of these emerging technologies is to be decided. Patients are inheriting greater autonomy over how their personal information is shared and retained, but to what degree will this shift the clinician/patient relationship dynamic and empower patients?Hospitals and providers already face tight cost constraints, so how will new resource allocation priorities and the challenge of managing efficient data systems impact the quality of cancer care? With many patients travelling across Europe for treatments, will differences in implementing patient data guidelines create tensions for quality care and which stakeholders will be most affected? For stakeholders in oncology, GDPR means that any organization handling the data of an EU citizen must be ready for a new era of healthcare compliance to safeguard patient information. This backdrop of evolving regulation coupled with a rise in cybersecurity attacks like the NHS data.

Chris Fearne

Deputy prime minister and minister of health, Malta

Chris Fearne

Deputy prime minister and minister of health, Malta

Minister Christopher Fearne was born in Attard, Malta on 12 March 1963. In April 2016 he was appointed minister for health after holding the position of parliamentary secretary for health since April 2014. In June 2017 he was re-appointed minister for health following the general elections and in July 2017 he was elected deputy prime minister following the Malta Labour Party’s extraordinary general council. Prior to this, Hon. Fearne worked as a consultant paediatric surgeon and clinical chairman at Mater Dei Hospital. He is a member of parliament for the ruling Labour Party and was the chairman of the foreign and European affairs committee at the Maltese house of representatives. Hon. Fearne has worked as a doctor and surgeon for over 30 years. He received his formal education at St. Aloysius College and at the University of Malta graduating in medicine and surgery in 1987, becoming a fellow of The Royal College of Surgeons of Edinburgh. He worked and studied in a number of children’s hospitals in England, including the Great Ormond Street Hospital in London. He also lectures students of medicine at the University of Malta.

Liz Barrett

Chief executive officer, Novartis Oncology

Liz Barrett

Chief executive officer, Novartis Oncology

Liz Barrett has been chief executive officer of Novartis Oncology since February 1, 2018. She is a member of the executive committee of Novartis.

Ms. Barrett previously served as global president of oncology at Pfizer Inc. At Pfizer, she held other leadership positions, including president of global innovative pharma for Europe, president of the specialty care business unit for North America, and president of United States oncology. Prior to Pfizer, she was vice president and general manager of the oncology business unit at Cephalon Inc. from 2006 to 2009, and before that, she worked at Johnson & Johnson. She started her career at Kraft Foods Group Inc. in 1984.

Ms. Barrett holds a Bachelor of Science from the University of Louisiana and a Master of Business Administration from Saint Joseph’s University, both in the US

Suzanne Wait

Managing director, The Health Policy Partnership

Suzanne Wait

Managing director, The Health Policy Partnership

Suzanne Wait is co-managing director of The Health Policy Partnership (HPP), a London-based consultancy specialising in health policy and research (www.heathpolicypartnership.com). Over the past fifteen years, Suzanne has helped run a number of multi-stakeholder policy initiatives, covering topics such as cancer, hepatitis, diabetes, immuno-oncology, stroke prevention and cardiovascular disease. The challenge of inter-sectoral and multi-disciplinary working has been a focal thread across all her work, as well as the need for sustainable and patient-focused health care systems.

Suzanne’s work in oncology has looked at the challenges specific to rare cancers and ways to improve the efficiency and patient-centricity of cancer care. Since 2016, her team at HPP has provided secretariat for a multi-stakeholder group called All.Can (www.all-can.org), which aims to engage policymakers on the need to focus on improving patient outcomes across cancer care. All.Can is currently conducting extensive research to gather patient perspectives on waste and inadequate outcomes across the cancer care continuum. They are also working on a large collaborative project with ICHOM on value-based cancer care.

Prior to starting HPP, Suzanne was director of research at the International Longevity Centre-UK, taught at the School of Public Policy at University College London, and was a Nuffield Trust Research Fellow at the Judge Institute of Management at Cambridge University. She also worked for Novartis and Bristol-Myers Squibb in their outcomes research/health economics departments. Originally from Canada, Suzanne has a Masters of Public Health from Columbia University and a PhD in Public Health from the University of Strasbourg. She is fluent in English, French, Italian and Spanish and has good working knowledge of German.

9:55 AM

Research presentation from the EIU: Cancer Preparedness Index

The Economist Intelligence Unit will present their ongoing research programme on the Cancer Preparedness Index.

Alan Lovell

Alan Lovell

Alan is a Senior Associate and Information Services Manager at EIU Healthcare. He is a member of the Health Policy and Clinical Research team, and oversees the horizon-scanning, searching, collating and appraisal work for evidence reviews and health technology appraisals. Alan has advised and worked on a range of projects for governments, health ministries, academic journals, healthcare providers, insurers, research funders, pharmaceutical companies and sporting associations. Key clients that he has worked with include the National Institute for Health and Care Excellence, the National Institute of Health Research Dissemination Centre and the Map of Medicine. Alan studied biology at Royal Holloway, University of London, and gained his doctorate from the University of Warwick. He worked at the University of Montreal, before receiving his MA in Information Studies from Brighton University. Alan has an interest in evolution and is a Fellow of the Linnaean Society of London.

10:15 AM

Digital technologies: strengthening infrastructure and patient care

Oncology thought leaders across Europe are leveraging data platforms to improve patient diagnosis, treatment and care. From the Nordic genomic data bases, to NHS digital health initiatives, to Iceland’s cancer registry, which countries are outpacing the rest in infrastructure development? This panel will convene experts across Europe to discuss case studies on digital innovation and the impact on cancer care.

Giske Ursin

Director, Norwegian Cancer Registry

Giske Ursin

Director, Norwegian Cancer Registry

Giske Ursin is the director of the Cancer Registry of Norway, which is among the oldest cancer registries in the world and collects data on incidence and treatment of cancer, and administers the national cancer screening programmes. She is also a professor at the Institute of Basic Medical Sciences of the University of Oslo, and professor emeritus of the Department of Preventive Medicine at the University of Southern California. Ms Ursin is an internationally recognised cancer epidemiologist and is a member of the Norwegian Society of Science and Letters. Her research has focused on the epidemiology of cancer subgroups, defined by pathological or genetic characteristics, as well as early markers for cancer. In addition, she currently serves as vice-chair of the Scientific Council of the International Agency for Research on Cancer, and is also a member of the Danish Cancer Society Scientific Committee and the steering group of the National Cancer Institute Cohort Consortium.

Szabolcs Nagy

Co-founder, chief executive, Turbine

Szabolcs Nagy

Co-founder, chief executive, Turbine

Szabi leads Turbine’s team of AI researchers, biologists and doctors building AI-guided, simulated models of human cells to predict how compounds impact patients. Prior to taking Turbine from the lab to partnering with top pharma, Szabi gained experience in bringing deep tech to success while launching Tresorit, a cryptography platform enabling secure data exchange through the cloud. His interest in helping patients developed while building a platform for managing chronic conditions with the Medical Futurist, the world’s leading thinker on digital health

Dan Simpson

Co-founder, CODE Initiative

Dan Simpson

Co-founder, CODE Initiative

Dan Simpson is a Vice President at IQVIA, the Human Data Sciences company, with over 20 years’ experience consulting to healthcare and pharma companies in a career spanning Cambridge Pharma, Accenture, Monitor/ Deloitte and, for the last 5 years, IQVIA. For the last 10 years, Dan has focussed on Real World Data (RWD) and its application in understanding the true impact on cost and outcomes of the application of assets in healthcare. As a co-founder of the CODE initiative (www.code-cancer.com) and in his role managing a Pan-European team focussed on finding and using oncology electronic medical record and registry data to answer difficult scientific questions, Dan is no stranger to the practicalities of day to day working with the healthcare sector to develop novel partnerships which are fair, valuable, efficient and explicitly safe and compliant in the use of patient data. He has championed the development of numerous major novel long-term partnerships between suppliers to oncology healthcare and healthcare institutions themselves, and has many more in the pipeline. These typically take the form of evidence platforms which are a commercial, legal, IT and process framework in which Pharma and Healthcare can efficiently and appropriately collaborate for the generation of new scientific insights.

10:55 AM

Networking break

11:25 AM

In conversation: promises and pitfalls of patient access to data

Do the benefits of data sharing for researchers, clinicians and patients outweigh the risks of data breaches and privacy violations?

Neil Bacon

President and CEO, ICHOM

Neil Bacon

President and CEO, ICHOM

In October 2018, Dr Bacon was appointed as President and CEO of the International Consortium of Health Outcomes Measurement (ICHOM), a non-profit organisation focused on transforming healthcare worldwide by defining international standards for the outcomes that matter most for patients and supporting healthcare providers to measure in practice.

An Oxford and Harvard trained nephrologist with a clinical and academic career spanning 18 years, Neil Bacon founded the award winning Doctors.net.uk, growing it to become the world’s largest, online medical network. The contribution this has made to healthcare for patients – was recognised when he was made a Fellow of the Royal College of Physicians in London. After 12 years leading Doctors.net.uk he successfully exited to launch iWantGreatCare.org: the only open, independent service allowing patients to rate and review their doctors, nurses, dentists, physios, hospitals, medicines and treatments, giving patients and the public unprecedented power to feedback and improve the care they receive.

The combination of entrepreneurial leadership, international clinical experience, innovative delivery of proven online healthcare solutions, and an understanding of the power of the “armchair auditor” to drive transformation of public service, has led to a busy and varied schedule. Dr Bacon has advised a number of the world’s largest companies, not for profits, public-sector organisations and government on multi-channel health strategies, patient-outcomes and clinician-engagement - helping them transform what they do through using the Internet to make real change that impacts lives. In 2013 Dr Bacon was recognised as a UK clinical leader of the year; in the same year he was also included in the list of the UK’s Health Innovators of the Year.

In 2014 the Sunday Times identified Dr Bacon as one of the 500 most influential people in Britain.

Ophira Ginsburg

Medical oncologist, New York University

Ophira Ginsburg

Medical oncologist, New York University

Dr. Ginsburg is medical oncologist with expertise in cancer genetics, epidemiology, prevention,
and screening. An Associate Professor in Medicine and Public Health at the University of
Toronto until 2015, she is now based at New York University where she serves as Director of
the High-Risk Cancer Genetics Program at the Perlmutter Cancer Center and is Associate
Professor, Section for Global Health, Department of Population Health at NYU Langone Health.

Tim Williams

Co-founder & CEO, My Clinical Outcomes

Tim Williams

Co-founder & CEO, My Clinical Outcomes

Tim Williams founded My Clinical Outcomes (MCO) in 2011 having become frustrated at the lack of real-world outcomes data available to inform patient care while working as a doctor and management consultant in the NHS. Prior to this he studied medicine at Balliol College, Oxford and Guys and St Thomas’ Hospitals in London. MCO is a patient-centred digital health platform that makes Patient-Reported Outcomes measurement and analytics available to inform clinical decisions and make all care pathways more effective and efficient. A 2017 RCT (Basch et al.) showed that remotely collected outcomes data could help significantly improve the survival of patients with advanced cancer. MCO is currently live at over 60 UK hospitals, including a range of oncology projects such as with NHS Scotland through the ‘Cancer Innovation Challenge’ supporting patients undergoing chemotherapy, as well as Macmillan and the Royal College of Radiologists to support the long-term follow-up of radiotherapy patients. He is an early advocate of the need for cost-effective digital technology and data to support the widespread adoption of Value-Based Healthcare and has undertaken Professor Michael Porter's Value-Based Healthcare seminar at Harvard Business School. MCO is an affiliate of the Private Healthcare Information Network (PHIN) in the UK and the International Consortium of Health Outcomes Measurement (ICHOM).

12:05 PM

Power of online platforms and demographic divides

Patient support groups, diagnosis and clinician follow ups are being reinvented through digital channels. Enabled by social media, mobile technologies and online platforms, what will the future of patient communities and engagement with stakeholders look like? Is online overblown and will younger generations have a competitive advantage
on leveraging resources, compared to older generations who did not grow up in the digital age?

Shafi Ahmed

Chief medical officer, Medical Realities

Shafi Ahmed

Chief medical officer, Medical Realities

Professor Shafi Ahmed is a multi award winning surgeon, teacher, futurist, innovator and entrepreneur. He is a 3x TEDx and an international keynote speaker and is faculty at Singularity University. He is a cancer surgeon at The Royal London and St Bartholomew’s Hospitals and has been awarded the accolade of the most watched surgeon in human history. As a dedicated trainer, educator, and Associate Dean of Bart’s Medical School, he was awarded the Silver Scalpel award in 2015 as the best national trainer in surgery by the Association of Surgeons in Training. He is currently serving as an elected member of council of the Royal College of Surgeons of England where he is the Director of the International Surgical Training Programme. He is an honorary visiting professor at The University of Bradford where he delivered the Cantor Lecture of Technology in 2017 and the public lecture to open the Digital Health Enterprise Zone. In 2017 he was the top British Asian star in Tech and received this award from HRH Duke of York. In 2018 he was awarded The Future NHS award by the Members of Parliament. His mission is to merge the world of medicine, global education, and virtual and augmented reality to democratize and scale surgical education to make it affordable and accessible to everyone using the power of connectivity to allow equitable surgical care. He cofounded Medical Realties who have just released the worlds first VR Interactive Surgical Training Module. He is a non-executive director of Medic Bleep, a communications platform for healthcare professionals. He is an advisor for companies working in Digital Health, Artificial intelligence and Robotics. He recently disrupting the traditional medical school curriculum by launching the Barts X Medicine Programme which has embedded future technologies and entrepreneurship into the medical school. He also chairman and a co-founder of the Global Innovation and New Technologies conference in London and Chair of WEBIT Health, Bulgaria.

Mark Lee

Senior vice president, head of personalized health care, Roche

Mark Lee

Senior vice president, head of personalized health care, Roche

Mark Lee is a medical oncologist and the Global Head for Personalized Healthcare, Product Development at Genentech/Roche. Prior to joining Genentech, Mark was a member of the founding leadership team and Head of Clinical Development and Medical Affairs at GRAIL, where he built one of the largest clinical research programs in genomic medicine aimed at early cancer detection. Mark’s previous roles include Lead for Oncology Clinical Sciences at Google[x] Life Sciences, Chief Medical Officer at Boreal Genomics, and Vice President of Oncology Development at Genomic Health, where he led the successful development and validation of the Oncotype DX Colon and Prostate Cancer Assays. His prior work also includes design and conduct of clinical trials for tissue-based and molecular imaging biomarker discovery at Genentech. Mark holds a PhD in Biological Chemistry and Molecular Pharmacology from Harvard, and a MD from Stanford University, where he completed his internal medicine training and medical oncology fellowship.

Sarunas Narbutas

Sarunas Narbutas

Šarūnas Narbutas is a professional lawyer, a political advisor and a cancer patient advocate, who has lived with chronic myelogenous leukemia (CML) for more than 10 years. Šarūnas is a President of Lithuanian Cancer Patient Coalition (POLA), deputy chairman of Lithuanian Patients’ Forum, co-founder of Youth Cancer Europe and holds several other management positions at international patient organisations, while serving on a dozen governmental committees or working groups. Until 2017, Šarūnas Narbutas has also served as a political advisor to the President of the Republic of Lithuania. Outside of the patient advocacy activities, Šarūnas is a chairman of Government Fund on the Promotion of Public Health, is a Member of National Health Council, a member of Lithuanian E-Health Management Board and a business ambassador for Governmental Agency “Invest Lithuania”. Šarūnas currently works on his PhD thesis on Networked Government and delivers lectures in Vilnius University Faculty of Law on Health Law, European Union Law and Public International Law.

12:45 PM

Lunch and networking

2:00 PM

STRATEGY SESSIONS (CONCURRENT)

Interactive breakout sessions will take place immediately after the lunch breaks - attendees have the choice of two sessions to attend:

2:00 PM

Strategy session: Breakthrough therapies and the technology for treatment in 2020

sponsored by Novartis

What are the breakthroughs, from CAR-T to dendritic cell therapies that are reinventing the future of patient treatments? What is the scope for taking these therapies to scale and what will future financing of these initiatives look like?

Andrew Sewell

Distinguished research professor, Cardiff University School of Medicine

Andrew Sewell

Distinguished research professor, Cardiff University School of Medicine

My research is focused on immune cells called T-cells that play a vital role in protecting us from infection. T-cells also have the capacity to recognise and eliminate cancer cells. Harnessing this effect in the form of cancer immunotherapy is now a first line treatment for some cancers. We work with a number of commercial partners in the UK with a view to developing new immunotherapies.

Bryan Deane

Head of product & process innovation, Association of the British Pharmaceutical Industry

Bryan Deane

Head of product & process innovation, Association of the British Pharmaceutical Industry

After graduating in Pharmacology and completing a PhD in Neuropathology, Bryan embarked on a long and successful career in the pharmaceutical industry. A series of increasingly senior positions at SmithKline Beecham and GlaxoSmithKline were mostly focussed on medical marketing and commercial development, covering a variety of therapy areas including infectious diseases, oncology, respiratory and diabetes. These positions included experience in a wide range of countries and regions, from the UK and Europe to China and from Latin America to Asia-Pacific. Over the last 10 years, Bryan has led a variety of projects as a freelance consultant, including support for new product launches, medical affairs and restructuring healthcare agencies. Since 2012, a joint project with the ABPI investigating the topic of clinical trial transparency led to four peer-reviewed publications, and Bryan joined the ABPI’s Research, Medical & Innovation Team in May 2018, with a focus on Antimicrobial Resistance and Advanced Therapy Medicinal Products.

Jonathan Pearce

Regional Director Europe, Lymphoma Coalition Europe

Jonathan Pearce

Regional Director Europe, Lymphoma Coalition Europe

Jonathan has over 15 years’ experience as a charity chief executive in the UK. Before
starting work for Lymphoma Coalition Europe in March 2018, he was the chief executive of
Lymphoma Action (formerly the Lymphoma Association) for four years, and before that
Adoption UK and Cabrini Children’s Society. In his LCE role, he is a member of the
European Cancer Organisation’s (ECCO) Patient Advisory Committee and of the European
Haematology Association’s European Affairs Committee.
He is also Chair of Cancer52 (a UK national alliance of charities representing rare and less
common cancers), and has a background in the voluntary sector, law, publishing and
journalism.

Mark Haefele

Mark Haefele is the Chief Investment Officer of UBS Global Wealth Management and the Chair of the UBS Global Investment Committee. In this capacity, Mark oversees the investment strategy for USD 2.4 trillion in invested assets, including UBS's oncology impact investing strategy.

Mark joined UBS as Head of Investment for UBS Wealth Management's Chief Investment Office when it was founded in 2011. Before joining UBS, Mark was the co-founder and co-fund manager at Sonic Capital. He also served as a Managing Director at Matrix Capital Management and began his career as a lecturer and subsequently acting dean at Harvard University.

Mark received a BA from Princeton and both an MA and a PhD from Harvard. As a Fulbright Scholar, he also received an MA from the Australian National University.

Elizabeth Sukkar

Editor, Economist Intelligence Unit

Elizabeth Sukkar

Editor, Economist Intelligence Unit

Elizabeth Sukkar is an editor in the Economist Intelligence Unit’s Thought Leadership team. She has been a journalist and editor for more than 15 years, covering healthcare policy, R&D and science for medical journals and UK newspapers, including the British Medical Journal and the Guardian. Before joining the EIU, she was the deputy news editor at the Royal Pharmaceutical Society, where she ran the news and analysis desk, and was often called to comment about healthcare issues on BBC radio. She also managed a team of international journalists when she was the world editor of Informa’s Scrip Intelligence, a global publication on pharmaceutical and healthcare policy, where she won the Informa Journalist of Year award. Before moving into journalism, Elizabeth worked as a pharmacist in community, hospital and health authority settings.

2:00 PM

Strategy session: radiation oncology

What are the latest game-changing technologies in radiology and radiation oncology and are they meeting patient objectives? What is the patient’s role in strengthening efficacy of future initiatives? What are the largest barriers to taking promising innovations to scale?

Ricky Sharma

Chair of radiation oncology, University College London

Ricky Sharma

Chair of radiation oncology, University College London

Professor Ricky Sharma is Chair of Radiation Oncology at University College London and the Head of Academic Radiotherapy at the UCL Cancer Institute. He is an Honorary Consultant in Clinical Oncology at University College London Hospitals and the Royal Free Hospital, where he has a clinical practice in radiotherapy and chemotherapy. He graduated in medicine from the University of Cambridge, United Kingdom. He trained in general internal medicine, medical oncology and radiation oncology and completed a PhD on DNA damage repair. Prior to his current post, Professor Sharma was an Associate Professor and Scientific Group Leader at the University of Oxford, where he was an Honorary Consultant in Clinical Oncology. Professor Sharma is an international authority on the translation of radiobiology from the laboratory to the clinic and on the multi-modality treatment of cancer with precision therapy.

Sukhveer Singh

Sukhveer Singh

Sukhveer Singh is the vice-president and general manager for the Oncology Continuum Solutions (OCS) business unit at Varian Medical Systems located in Palo Alto, California. The mission of OCS is to enable global providers of cancer treatment to deliver high-quality, cost-effective, patient centric, coordinated multi-disciplinary care. Sukhveer is a technology enthusiast and maven. He believes in the transformational potential of informatics and is an evangelist for the adoption of mobility, big data, cloud-computing, and personalized medicine within healthcare.

Sukhveer has more than 18 years of international leadership experience in the healthcare and strategic consulting space, most notably with companies such as Philips, Siemens, and Bridge Strategy. He has expertise in product marketing, product development, service marketing, complete life-cycle software development, offshoring management, and cross-functional team management. He also plays an active role in organization wide strategic and operational initiatives like change management, value based pricing, and business processes optimization. Sukhveer has a B.S. in Engineering from Netaji Subhas Institute of Technology, an M.S. in Computer Science from Illinois Institute of Technology, and is a 2004 MBA graduate from the Kellogg School of Management at Northwestern University.

Mark Gooding

Chief scientist, Mirada Medical

Mark Gooding

Chief scientist, Mirada Medical

Dr Gooding obtained his DPhil in Medical Imaging from University of Oxford in 2004. He was employed as a postdoctoral researcher both in university and NHS settings, where his focus was largely around women’s health. In 2009, he joined Mirada Medical, motivated by a desire to see technical innovation translated into clinical practice. While there, he has worked on a broad spectrum of clinical applications, developing algorithms and products for both diagnostic and therapeutic purposes. If given a free choice of research topic, his passion is for improving image segmentation, but in practice he is keen to address any technical challenge. Dr Gooding now leads the research team at Mirada, where in addition to the commercial work he continues to collaborate both clinically and academically.

3:00 PM

In conversation: making Mind The Dash

Mind The Dash is a recent documentary featuring 11 people who have or have had cancer. Over 3 months they were trained in filmmaking skills in collaboration with the local Macmillan support team. The final 30 minute film is a moving portrayal of three of those individuals, two under the age of 30. Hear from the director and one of the participants on their experience making the documentary.

Sarah Davis

Artist

Sarah Davis

Artist

Sarah Davis is an artist based in East London. Her work is focused on the
sculptural documentation of ill health. In January 2017 at the age of 26, Sarah was diagnosed with Hodgkin’s Lymphoma. What initially should’ve taken 6 months to cure turned into a menagerie of failed treatments, which finally culminated with a successful Stemcell transplant in February 2018.

With a different body, outlook on life and an imbued sense of confidence Davis sought to document her personal journey of ill health, which led her to take part in the performance and noise art Biennial tempting failure. For the biennial Davis spent 3 days working in situ making multiple plaster casts of all the empty pill packets and medical ephemera she had collected over the previous 15 months.

The outcome functioned as a visual representation of ill health and as a
testament to what the body can endure and recover from. Since documenting her own experience Davis intends to take the project further by helping others to process their own illnesses through sculptural documentation.

www.sarahgdavis.co.uk
As part of her summer of recovery, Davis also took part in a documentary
filmmaking course funded and facilitated by Macmillan cancer support and the Bromley-by-Bow centre. The course bought together 11 people directly affected by cancer. As well as learning multiple new film making skills, Davis also gained a support network of friends and fellow Cancer fighters.

Dieter Deswarte

Documentary filmmaker

Dieter Deswarte

Documentary filmmaker

Dieter Deswarte is an awarded documentary filmmaker based in London. He is a self-shooter and editor. His intimate approach leads to a low-intervention kind of filmmaking that captures human stories with sincerity, creativity and cinematic beauty. He is one of the core lecturers on the MA in ethnographic and documentary film at UCL where he runs a studio entitled: Cinematic Documentary Storytelling. In the past few years he has led several collaborative filmmaking projects with a diversity of community groups from youth offenders to women who suffered domestic and sexual violence. This has given him a wealth of experience and understanding on how to support and work with vulnerable groups.

3:20 PM

Networking break and screening of Mind The Dash

4:00 PM

Talking through taboos

Blogs and podcasts reach a mass audience and inform and engage people without the didactic approach of traditional awareness-raising medical campaigns. How are these new mediums helping to break down the many taboos and misunderstandings around cancer, familiarise readers and listeners with the language of diagnosis and treatment, and let people hear directly from patients on their view of the big issues around cancer?

Deborah James

Host, You, Me and the Big C

Deborah James

Host, You, Me and the Big C

Deborah James was a deputy head teacher leading national research teams into growth mindsets in schools. Then, in 2016, at the age of 35, she was diagnosed with bowel cancer and her life with her young children and husband was thrown upside down. She's had 4 major operations including bowel and lung resections, multiple rounds of chemo and Cyberknife - and is still undergoing treatment at the Royal Marsden. Rather than disappear into a cancer cave she started a blog, 'bowel babe' to debunk the myth that young women don't get bowel cancer and writes a weekly column for the Sun online, Things Cancer Made Me Say. He first book “She campaigns alongside major UK cancer charities, writes and presents the award winning podcast 'You, Me & the Big C' for BBC's Radio 5 Live, and has a built up a strong following on Instagram @bowelbabe. Her best selling book - “F*** You Cancer” a self help guide to living your best life WITH cancer, published by Penguin is out now.

Lauren Mahon

Host, You, Me and the Big C

Lauren Mahon

Host, You, Me and the Big C

Lauren has never been a big fan of her boobs. If you can even call them that. They’re more of a nod to a boob, a flabby-nipple-type situation, a goodwill gesture. So on the 31st August 2016 when following a biopsy a Dr uttered the words “I’m sorry, it’s not good news, it’s cancer” she was sure they were having a f*cking laugh.

Surely this must be the universe’s idea of a cruel joke. Right? Firstly Lauren was thirty-bloody-one, far too young and full-of-fun to be dealing with this kind of crap, and secondly, how can she have breast cancer when she DOESN’T HAVE ANY B*STARD TITS?!?!

But Lauren did have breast cancer. An aggressive 2.8cm ‘Grade 3’ cancerous lump set up residence in her right chesticle, without consent, and sent her life as she knew it into a tailspin.

Desperate for some reassurance and carcinoma companionship Lauren went looking for like-minded women who had faced the c-bomb for advice and encouragement. Unfortunately she mostly found doomsaying online communities and clinical materials that were aimed at women in a more advanced lifestage. It didn’t speak to her. At all.

Fed up of the perception that cancer is a disease for the over fifties Lauren decided to grab her breast cancer diagnosis by the boobs and began sharing the nuances of her cancer beating crusade on her blog and instagram under the hashtag #GIRLvsCANCER. Lauren’s aim was to share the tales of her treatment in an authentic and accessible way in an attempt to tackle the cancer taboo and create a better understanding of the challenges facing those diagnosed with cancer in their 20’s + 30’s.

Lauren also wanted her miniature space on’t interweb to empower her peers. Encourage them to take responsibility for their bodies. Know them like they know all the lyrics to Drake’s Hotline Bling because by being in tune with yourself you’ll know when something is in need of examining.

After all if a fit and feisty Lauren could get cancer, anyone can.

And thus GIRLvsCANCER was born – a place for fierce women affected by the cretin that is cancer to feel empowered to deal with the sh*t show that a cancer diagnosis means.

4:25 PM

Inequitable access: global contexts and socio economic divides

Universal healthcare coverage in Europe may cover procedures, but consumer health technology remains an out of pocket expense. Could technology worsen the divide between low-income and high income countries’ access to care or finally be the great equalizer?

Liselott Blixt

Chair, health and senior citizen's committee, and member of parliament, Denmark

Liselott Blixt

Chair, health and senior citizen's committee, and member of parliament, Denmark

Mitesh Patel

Medical director, Aetna International

Mitesh Patel

Medical director, Aetna International

As medical director for Aetna International, Mitesh provides guidance, support, and medical leadership for care management activities in Europe. Mitesh also manages Aetna International’s emergency evacuation program, helping to ensure appropriate healthcare delivery for our members around the globe. Mitesh is an established “Thought Leader” having published numerous whitepapers which cover topical issues ranging from expatriate mental health, globesity and the ticking time bomb of the ageing population. Dr. Patel graduated from King’s College University, London and also has a Healthcare Management degree from Imperial College, London. He is also a practicing physician in Emergency Medicine.

Markus Kosch

Global Lead Immuno-oncology, Kidney and Lung Cancer, Pfizer

Markus Kosch

Global Lead Immuno-oncology, Kidney and Lung Cancer, Pfizer

Professor Dr. Markus Kosch joined Pfizer in 2010 as Commercial Lead Pfizer Oncology Europe, Hematology. After roles of increasing responsibility at the regional level, he took over the Lead of Pfizer Oncology in Germany and the role as one of the General Managers of Pfizer Pharma GmbH. In 2015 he was appointed Vice President Commercial Portfolio Management Oncology Europe, Africa, and Middle East. Since June 2016 he is Vice President Oncology Portfolio, Europe, Japan and developed Asia.

After earning a doctorate in medicine in 1997 from the University of Münster in Germany, Markus treated cancer and leukemia patients in the university hospital's department of internal medicine, most recently as senior physician. After eight years of clinical practice, he made the transition to the research-based biopharmaceutical industry as Medical Lead, Specialty Care, Vaccines and Oncology at Wyeth Germany in 2005.

In the ensuing years of his business career, he continued to pursue his keen interest in
clinical practices and university-based research, and has since 2008 also been a teaching
Professor for Internal Medicine at the university of Münster.

He has just been appointed to globally lead Pfizer’s business in Immuno-Oncology, Lung-
and Kidney cancers.

Martin Koehring

Martin Koehring is a managing editor at The Economist Intelligence Unit's thought leadership division in EMEA. He is also global editorial lead for the healthcare sector and has led major research projects in healthcare, for example on access to healthcare, heart health, global cancer survivorship, chronic diseases in developing countries, tackling obesity, the policy response to diabetes and value-based healthcare. Before joining The EIU's thought leadership team in 2014 he was Europe editor in The EIU's Country Analysis team, covering politics, economics and industry trends in Western Europe. In addition to English and his native German, he also speaks Dutch, French and Italian. Prior to joining The EIU in 2011, Mr Koehring worked as a senior economist at the business intelligence provider Dun & Bradstreet. Mr Koehring earned a bachelor of economic and social studies in international relations (First Class Honors) from Aberystwyth University and a master’s degree in EU international relations and diplomacy studies from the College of Europe. He has also studied macroeconomics, international economics and global health policy at the University of London. Mr Koehring is an experienced public speaker. He has presented EIU research to audiences across the globe, for example in Geneva (on global heart health), Brussels (on obesity in Europe) and Belgrade (on modernising healthcare systems in the Balkan countries).

5:05 PM

Closing remarks

Roundup of the day’s discussion and also findings from WOC Asia, London, Latin America and Dubai.

5:15 PM

Conference close

Venue

The Waldorf Hilton

Sponsors

Research sponsors

Novartis

Novartis is a world-leading healthcare company. We focus where our skills can help address great medical need in Oncology, Cardiovascular, Respiratory, Neuroscience, Immunology and dermatology, Eye care

Research sponsors

Pfizer

At Pfizer, we strive to set the standard for quality, safety and value in our health care products. Every day, Pfizer colleagues work to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. As one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world.

Research sponsors

Roche

The Roche Group is the world's leading provider of cancer care products. Our anti-cancer medicines are saving lives and significantly advancing the way some cancers are treated. In addition, Roche is developing new diagnostic tests that will have a significant impact on disease management for cancer patients in the future.

Silver sponsors

Silver sponsors

AbbVie

At AbbVie we work in partnership to discover and develop medicines that deliver transformational improvements in some of the most debilitating and widespread cancers. We are striving to outsmart cancer, together.

Silver sponsors

Takeda Pharmaceuticals International AG

We endeavor to deliver novel cancer medicines through our commitment to science, breakthrough innovation and our passion for improving the lives of patients. At Takeda Oncology we aspire to cure cancer.

Host sponsor

Elekta

Video sponsor

Philips

Royal Philips is a leading health technology company focused on improving people's health and enabling better outcomes. Philips leverages advanced technology, deep clinical, and consumer insights to deliver integrated solutions.

Accredited by

Accredited by

CPD Certification Service

Established in 1996, The CPD Certification Service is the independent CPD accreditation centre working across all sectors, disciplines and further learning applications. War on Cancer 2018 is eligible for 5.5 CPD points which The Economist Events can assist with claiming post-event.

Supporting associations

Supporting organisation

The Union for International Cancer Control (UICC)

The Union for International Cancer Control (UICC) is the largest and oldest international cancer-fighting organisation. Founded in Geneva in 1933, UICC has over 1,100 members in 170 countries, enjoys consultative status with the United Nations (ECOSOC) and has official relations with the following institutions: WHO, IARC, IAEA, UNODC. UICC has over 50 partners, including associations working to fight cancer, as well as companies and foundations. UICC is a founding member of the NCD Alliance, McCabe Centre and ICCP.

UICC’s mission is to unite and support the cancer community to reduce the global cancer burden, to promote greater equality and to ensure that the cancer control continues to be a priority in the world health and development agenda. Its main areas of activity focus on convening the world's leaders for innovative, wide-reaching, cancer-control events and initiatives; building capacity to meet regional needs; and developing awareness campaigns.

Supporting organisation

The EIU Healthcare

Supporting organisation

EFPIA - European Federation of Pharmaceutical Industries and Associations

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

Supporting organisation

European Association for Cancer Research

The EACR is a global community of cancer researchers with over 10,000 members in 101 countries. We provide a wide variety of services to our community of members, organise scientific conferences of the highest quality, and facilitate communication and collaboration within the cancer research community.

Supporting organisation

E-CANCER

ecancer.org is a vast, free online knowledge bank developed to help get the best outcomes for patients by supporting healthcare professionals improve their practice behaviours.

Media partner

European Medical Journal

The European Medical Journal is an independent, open-access eJournal dedicated to delivering first-class insights into ground-breaking changes, and advancements in medicine. Spanning sixteen therapeutic areas, including Innovations, Cardiology, Oncology, and more, each journal provides the reader with the latest medical congress highlights, abstract reviews, and peer-reviewed articles to name but a few of its wide content selection. Flagship EMJ journals are also published quarterly, bringing an assortment of research papers from a variety of topics.

Media partner

Pharmaphorum

Pharmaphorum is a content and communications company offering a unique hybrid of publisher and agency working in pharma and healthcare.pharmaphorum.com is our own independent flagship publication. It serves over 3 million unique users annually and its news and information is widely recognised as a leading source of thought leadership and strategic content for pharmaceutical professionals all over the world.Our innovative digital magazine Deep Dive provides cutting edge insight on pharma industry trends to an audience of 100K per issue.

Media partner

Touch Oncology

touchONCOLOGY.com is an independent information resource designed to support physicians, clinicians and related healthcare professionals in continuously developing their knowledge, effectiveness and productivity, with open access articles and multimedia content

Speaking opportunities

Sponsorship opportunities

Download Brochure

The Economist Events is a part of the Economist Group. We would love to keep you informed about other Economist events, newly-released content, our best subscription offers, and great new product offerings from The Economist Group.

I wish to be contacted by email.

I also wish to sign up to the EIU (Economist Intelligence Unit) Perspectives newsletter.

The Economist Group is a global organisation and operates a strict privacy policy around the world. Please see our privacy policy here

Attending Request

By submitting this form we will send you updates associated with this event.

The Economist Events is a part of the Economist Group. We would love to keep you informed about other Economist events, newly-released content, our best subscription offers, and great new product offerings from The Economist Group.

I wish to be contacted by email.

I also wish to sign up to the EIU (Economist Intelligence Unit) Perspectives newsletter.

The Economist Group is a global organisation and operates a strict privacy policy around the world. Please see our privacy policy here

Media partnership and press Request

By submitting this form we will send you updates associated with this event.

The Economist Events is a part of the Economist Group. We would love to keep you informed about other Economist events, newly-released content, our best subscription offers, and great new product offerings from The Economist Group.

I wish to be contacted by email.

I also wish to sign up to the EIU (Economist Intelligence Unit) Perspectives newsletter.

The Economist Group is a global organisation and operates a strict privacy policy around the world. Please see our privacy policy here